OPK,WGS Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change 0.00
Percentage change 0.00	%

Peers: LH DGX MYGN EXAS MEDP CMRX VNDA BCRX TECH CRL

| Held by: VTI IWM VB VXF IWN VBR VBK IBB VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-0.08	Insider Own	55.84%	Shs Outstand	671.61M	Perf Week	-4.44%
Market Cap	1.02B	Forward P/E	-	EPS next Y	-0.20	Insider Trans	0.33%	Shs Float	350.22M	Perf Month	-3.01%
Income	-39.03M	PEG	-	EPS next Q	-0.11	Inst Own	32.10%	Short Float	9.04%	Perf Quarter	-30.65%
Sales	689.37M	P/S	1.48	EPS this Y	-326.79%	Inst Trans	27.52%	Short Ratio	9.38	Perf Half Y	-18.87%
Book/sh	1.95	P/B	0.66	EPS next Y	40.17%	ROA	-1.90%	Short Interest	31.66M	Perf Year	3.20%
Cash/sh	0.55	P/C	2.35	EPS next 5Y	-11.20%	ROE	-3.04%	52W Range	1.19 - 2.04	Perf YTD	-12.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.04%	ROIC	-2.33%	52W High	-36.61%	Beta	1.37
Dividend TTM	-	Quick Ratio	2.28	Sales past 5Y	-4.59%	Gross Margin	20.02%	52W Low	8.40%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	2.49	EPS Y/Y TTM	82.82%	Oper. Margin	-39.05%	RSI (14)	39.38	Volatility	1.45% 2.01%
Employees	2997	Debt/Eq	0.37	Sales Y/Y TTM	-13.79%	Profit Margin	-5.66%	Recom	1.29	Target Price	3.99
Option/Short	Yes / Yes	LT Debt/Eq	0.28	EPS Q/Q	13.04%	Payout	-	Rel Volume	1.10	Prev Close	1.29
Sales Surprise	-8.74%	EPS Surprise	-45.77%	Sales Q/Q	-13.66%	Earnings	Apr 30 AMC	Avg Volume	3.37M	Price	1.29
SMA20	-3.32%	SMA50	-4.73%	SMA200	-15.46%	Trades		Volume	3,716,952	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-25-25	Initiated	JP Morgan	Neutral
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform	$2
Dec-15-22	Initiated	H.C. Wainwright	Buy	$3
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy	$7
Nov-25-19	Initiated	Piper Jaffray	Overweight	$2.50
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy	$16 → $18
Jun-03-16	Initiated	Standpoint Research	Buy	$16
Mar-31-16	Reiterated	Barrington Research	Outperform	$17 → $16
Oct-16-15	Initiated	JP Morgan	Overweight	$14
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform	$13 → $12
Mar-14-14	Initiated	Oppenheimer	Outperform	$13
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy	$10 → $14.50
May-30-13	Reiterated	Ladenburg Thalmann	Buy	$8.50 → $10
Oct-22-12	Initiated	Barrington Research	Outperform	$6
Dec-01-11	Reiterated	Ladenburg Thalmann	Buy	$6 → $8.50

Show Previous Ratings

Jun-13-25 12:37PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Jun-09-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development (GlobeNewswire)
May-15-25 08:00AM	OPKO Health to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-01-25 12:43PM	OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands (Zacks)
08:57AM	Q1 2025 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:17AM	Loading…
03:17AM	OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Apr-30-25 07:52PM	OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:50PM	OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	OPKO Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Apr-22-25 09:35AM	Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround (Zacks)
Apr-17-25 09:38AM	Labcorp Holdings: Regaining Credibility (Seeking Alpha)
08:00AM	OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 (GlobeNewswire)
Apr-11-25 04:05PM	NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program (PR Newswire)
08:00AM	Loading…
Apr-04-25 08:00AM	OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program (GlobeNewswire)
Mar-28-25 09:35AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Mar-18-25 11:37AM	Opko and Entera focus on oral care for obesity and metabolic disorders (Pharmaceutical Technology)
Mar-17-25 08:00AM	OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders (GlobeNewswire)
Mar-14-25 06:59PM	Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. (Barrons.com)
12:07PM	Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? (Insider Monkey)
Mar-12-25 12:10PM	Labcorp to acquire certain assets of Opko Healths BioReference Health (TipRanks)
11:06AM	Truist remains bullish on Labcorp after another nice strategic acquisition (TipRanks)
Mar-11-25 07:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Feb-28-25 09:01AM	Q4 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.75%
02:35AM	OPKO Health Inc (OPK) Q4 2024 Earnings Call Highlights: Strong Pharmaceutical Growth and ... (GuruFocus.com)
Feb-27-25 10:45PM	Opko Health (OPK) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00PM	OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates (Zacks)
05:58PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:10PM	Loading…
04:10PM	OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Feb-25-25 09:15AM	Countdown to OPKO Health (OPK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-13-25 04:05PM	OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-12-25 09:15AM	Is Opko Health Inc. (OPK) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Jan-27-25 08:00AM	Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-20-25 10:02PM	OPKO Health, Inc. (OPK) Stock: An Under $5 Gem with Biggest Upside Potential (Insider Monkey)
Jan-09-25 11:45AM	OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck (GlobeNewswire)
Dec-11-24 02:08AM	Is OPKO Health (OPK) the Best NASDAQ Penny Stock to Buy Right Now? (Insider Monkey)
Dec-10-24 08:00AM	NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer (PR Newswire)
Nov-29-24 02:43PM	Sleep Number, Getty Images, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-20-24 08:00AM	OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 08:00AM	NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo (PR Newswire)
Nov-15-24 08:34PM	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-14-24 06:00AM	NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results (PR Newswire)
Nov-08-24 04:05PM	Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates (GlobeNewswire)
04:01AM	OPKO Health Inc (OPK) Q3 2024 Earnings Call Highlights: A Turnaround in Profitability Amidst ... (GuruFocus.com)
Nov-07-24 10:15PM	Opko Health (OPK) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings (Zacks)
06:40PM	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
05:35PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference to Include OvaWatch (GlobeNewswire)
Oct-29-24 04:05PM	OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire) +6.67% -5.00%
Oct-07-24 08:00AM	NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan (PR Newswire)
08:00AM	ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program (GlobeNewswire)
Sep-25-24 08:30AM	Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders (GlobeNewswire)
Sep-23-24 08:00AM	OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development (GlobeNewswire)
Sep-16-24 07:30AM	Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health (PR Newswire)
Aug-09-24 04:05PM	Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-08-24 12:14PM	OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down (Zacks) +11.72%
12:15AM	Opko Health (OPK) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-07-24 08:00PM	OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:59PM	OPKO Health: Q2 Earnings Snapshot (Associated Press Finance)
04:06PM	OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-01-24 04:05PM	OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	OPKO Health Announces $100 Million Share Repurchase Program (GlobeNewswire) +7.04%
Jul-17-24 04:14PM	OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments (GlobeNewswire)
Jul-08-24 06:54PM	OPKO Health, Inc. (OPK): Most Shorted Stock Loved by Analysts Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-02-24 08:00AM	NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner (PR Newswire)
Jun-06-24 11:31AM	Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? (Zacks)
May-31-24 10:48AM	OPKO Health to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
10:00AM	The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now (InvestorPlace)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 09:18AM	OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y (Zacks)
May-08-24 11:47AM	OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:56AM	Q1 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:44AM	OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ... (GuruFocus.com)
May-07-24 09:15PM	Opko Health (OPK) Q1 2024 Earnings Call Transcript (Motley Fool)
08:30PM	OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:09PM	OPKO Health Inc (OPK) Q1 2024 Earnings: Misses Revenue and Earnings Estimates (GuruFocus.com)
05:30PM	OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:38PM	OPKO Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-03-24 08:00AM	OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-01-24 01:01PM	OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp (Zacks) +9.17%
Mar-28-24 11:08PM	Labcorp inks $237.5M buyout of Opkos reproductive, womens health testing assets (MedTech Dive) +12.15%
08:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business (PR Newswire)
Mar-25-24 09:57AM	OPKO Health (OPK) And Entera Bio Announce Data for GLP-2 (Zacks)
Mar-20-24 08:00AM	Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome (GlobeNewswire)
Mar-05-24 08:52AM	AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV (GlobeNewswire) -6.51%
Feb-29-24 08:31AM	OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 09:31AM	NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st (PR Newswire) -6.14%
09:02AM	OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top (Zacks)
06:18AM	Q4 2023 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 09:00PM	Opko Health (OPK) Q4 2023 Earnings Call Transcript (Motley Fool) +5.37%
07:30PM	OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:10PM	OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:08PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 10 '25	Buy	1.36	125,000	169,712	214,001,448	Apr 10 05:07 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 08 '25	Buy	1.48	125,000	184,650	213,876,448	Apr 08 05:34 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 01 '25	Buy	1.65	100,000	164,850	213,751,448	Apr 01 05:21 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 28 '25	Buy	1.70	150,000	254,385	213,651,448	Mar 28 05:22 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 17 '25	Buy	1.74	200,000	347,820	213,501,448	Mar 17 05:27 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Feb 28 '25	Buy	1.71	67,434	115,312	213,301,448	Feb 28 07:34 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 28 '25	Buy	1.47	47,537	70,060	213,234,014	Jan 28 05:40 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 17 '25	Buy	1.47	150,000	220,425	213,186,477	Jan 17 05:06 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 15 '25	Buy	1.48	500,000	740,850	213,036,477	Jan 15 05:18 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Dec 13 '24	Buy	1.59	125,000	199,375	212,536,477	Dec 13 05:04 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Dec 11 '24	Buy	1.56	500,000	781,050	212,411,477	Dec 11 05:21 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 29 '24	Buy	1.53	199,072	305,376	211,911,477	Nov 29 03:20 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 22 '24	Buy	1.59	100,000	159,000	211,712,405	Nov 22 05:17 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 14 '24	Buy	1.62	100,000	161,980	211,612,405	Nov 14 05:51 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 08 '24	Buy	1.50	280,183	421,535	211,512,405	Nov 08 05:40 PM
OPKO HEALTH, INC.	10% Owner	Sep 17 '24	Proposed Sale	40.88	13,404	547,956		Sep 20 02:56 PM
OPKO HEALTH, INC.	10% Owner	Aug 19 '24	Sale	34.49	50,000	1,724,520	2,646,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 16 '24	Sale	34.30	50,000	1,714,850	2,696,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 15 '24	Sale	33.08	39,824	1,317,505	2,746,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 12 '24	Sale	33.95	59,787	2,029,811	2,811,783	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 13 '24	Sale	34.76	24,987	868,503	2,786,796	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 08 '24	Sale	31.82	100,000	3,182,380	2,871,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Aug 06 '24	Sale	29.35	12,994	381,427	2,971,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Jul 31 '24	Sale	33.50	88,839	2,976,346	2,984,564	Aug 02 04:21 PM
OPKO HEALTH, INC.	10% Owner	Jul 29 '24	Sale	33.86	50,000	1,692,890	3,073,403	Jul 31 05:03 PM
OPKO HEALTH, INC.	10% Owner	Jul 24 '24	Sale	33.72	75,000	2,529,105	3,183,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 26 '24	Sale	33.85	60,000	2,031,258	3,123,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 23 '24	Sale	33.46	75,000	2,509,245	3,258,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 22 '24	Sale	32.61	50,000	1,630,440	3,333,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 19 '24	Sale	32.29	25,000	807,250	3,383,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 17 '24	Sale	32.93	25,000	823,188	3,408,403	Jul 19 06:46 PM
OPKO HEALTH, INC.	10% Owner	Jul 05 '24	Sale	28.24	36,118	1,020,016	3,433,403	Jul 09 04:07 PM
OPKO HEALTH, INC.	10% Owner	Jul 01 '24	Sale	26.63	50,000	1,331,700	3,508,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 02 '24	Sale	29.12	25,000	728,095	3,483,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 03 '24	Sale	28.23	14,082	397,491	3,469,521	Jul 03 04:56 PM

Dollar change +0.39
Percentage change 0.61	%

WGS GeneDx Holdings Corp daily Stock Chart

Peers: ILMN GH QDEL NTRA EXAS MYGN TWST CDNA CRSP VERV

| Held by: VTI VXF IWM FESM IWN SCHA VTWO VHT PINK FRTY

Index	RUT	P/E	-	EPS (ttm)	-1.44	Insider Own	12.50%	Shs Outstand	28.53M	Perf Week	-8.38%
Market Cap	1.84B	Forward P/E	31.77	EPS next Y	2.03	Insider Trans	-3.19%	Shs Float	24.97M	Perf Month	-9.28%
Income	-38.58M	PEG	-	EPS next Q	0.12	Inst Own	101.86%	Short Float	14.56%	Perf Quarter	-33.88%
Sales	330.14M	P/S	5.57	EPS this Y	319.52%	Inst Trans	26.88%	Short Ratio	3.38	Perf Half Y	-14.58%
Book/sh	9.02	P/B	7.14	EPS next Y	90.24%	ROA	-9.17%	Short Interest	3.64M	Perf Year	123.87%
Cash/sh	5.58	P/C	11.55	EPS next 5Y	120.75%	ROE	-16.61%	52W Range	24.91 - 117.75	Perf YTD	-16.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	96.65%	ROIC	-10.45%	52W High	-45.28%	Beta	2.01
Dividend TTM	-	Quick Ratio	3.07	Sales past 5Y	14.24%	Gross Margin	60.85%	52W Low	158.65%	ATR (14)	4.67
Dividend Ex-Date	-	Current Ratio	3.25	EPS Y/Y TTM	72.54%	Oper. Margin	-3.83%	RSI (14)	40.98	Volatility	3.51% 3.45%
Employees	1000	Debt/Eq	0.45	Sales Y/Y TTM	48.81%	Profit Margin	-11.68%	Recom	1.33	Target Price	95.00
Option/Short	Yes / Yes	LT Debt/Eq	0.43	EPS Q/Q	70.13%	Payout	-	Rel Volume	0.64	Prev Close	64.04
Sales Surprise	9.63%	EPS Surprise	365.65%	Sales Q/Q	39.56%	Earnings	Apr 30 BMO	Avg Volume	1.08M	Price	64.43
SMA20	-7.10%	SMA50	-16.39%	SMA200	-12.44%	Trades		Volume	685,324	Change	0.61%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-25	Initiated	Guggenheim	Buy	$88
May-09-25	Upgrade	Jefferies	Hold → Buy	$80
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$34
Jul-10-24	Initiated	Craig Hallum	Buy	$43
Jun-03-24	Resumed	Jefferies	Hold	$21

Jun-17-25 08:59AM	Zacks Industry Outlook Highlights CVS Health, BrightSpring Health Services and GeneDx (Zacks)
Jun-16-25 11:09AM	3 Medical Services Stocks Capitalizing on the Healthcare AI Boom (Zacks)
09:35AM	Here's Why ENSG Shares Are Attracting Prudent Investors Now (Zacks)
Jun-03-25 11:44AM	Ensign Enhances Presence With 3 New Acquisitions in 2 States (Zacks)
Jun-02-25 12:22PM	Here's Why You Should Hold Cigna Stock in Your Portfolio for Now (Zacks)
11:50AM	Loading…
May-30-25 11:50AM	Danaher Partners With AstraZeneca to Support Precision Medicine (Zacks)
09:32AM	COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down (Zacks)
09:31AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks)
May-29-25 09:55AM	Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know (Zacks)
09:29AM	Reasons to Retain The Cooper Companies Stock in Your Portfolio Now (Zacks)
May-28-25 09:40AM	Here's Why You Should Add Pediatrix Medical to Your Portfolio Now (Zacks)
09:14AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
May-27-25 11:17AM	Here's Why Encompass Health Shares Are Attracting Investors Now (Zacks)
May-23-25 04:03PM	Here's Why You Should Retain CONMED Stock in Your Portfolio for Now (Zacks) +6.34%
07:28AM	Brookdale Shares Down 4.9% Despite Q1 Earnings Meeting Estimates (Zacks)
06:02AM	Loading…
06:02AM	Insiders Pour Millions into These 3 Stocks Heres Why They Draw Plaudits Across the Board (TipRanks)
May-22-25 04:05PM	GeneDx to Participate in Upcoming Investor Conferences (Business Wire)
08:00AM	GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale (Business Wire)
May-21-25 07:17AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio (Zacks) -6.00%
May-19-25 07:02AM	Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now (Zacks)
May-16-25 08:00AM	Here's Why You Should Add DexCom Stock to Your Portfolio Now (Zacks) +7.39%
07:59AM	Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up (Zacks)
May-14-25 10:51AM	The Joint Misses Q1 Earnings Estimates on Rising Expenses (Zacks)
May-13-25 11:06AM	Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions (Zacks)
May-09-25 11:35AM	Pediatrix Medical's Q1 Earnings Beat Estimates on Declining Costs (Zacks)
May-08-25 12:31PM	Select Medical Lags Q1 Earnings Estimates, Lowers Revenue Outlook (Zacks)
11:39AM	TDOC Q1 Loss Narrower Than Estimates on Strong Integrated Care Unit (Zacks)
May-07-25 08:30AM	GeneDx Announces Completion of Fabric Genomics Acquisition (Business Wire) -9.37%
May-05-25 10:00AM	Best Momentum Stocks to Buy for May 5th (Zacks)
08:16AM	New Strong Buy Stocks for May 5th (Zacks)
04:23PM	Loading…
May-02-25 04:23PM	Why Investors Were Avoiding GeneDx Holdings Stock This Week (Motley Fool) +7.88%
May-01-25 10:30AM	GeneDx earnings selloff a buying opportunity, says Craig-Hallum (TipRanks) -6.78%
Apr-30-25 04:29PM	IBD 50's GeneDx, Down 43%, Was 'Priced For Perfection.' Here's What It Missed. (Investor's Business Daily) -42.85%
01:15PM	GeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
12:28PM	Why GeneDx Holdings Stock Is Plunging Today (Motley Fool)
08:53AM	IBD 50 Stock GeneDx Hammered Despite Earnings Beat-And-Raise (Investor's Business Daily)
07:45AM	GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates (Zacks)
06:30AM	GeneDx Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
Apr-29-25 12:00PM	GENEDX HOLDINGS (WGS) Upgraded to Buy: Here's Why (Zacks)
Apr-28-25 11:13AM	GeneDx: Strengthening Leadership In Genomic Diagnostics (Seeking Alpha)
Apr-25-25 10:54AM	Meta Stock Struggles, Tries To Bottom Ahead Of Q1 Results; These Growth Stocks Look Much Stronger (Investor's Business Daily)
Apr-23-25 05:46PM	GeneDx Holdings Corp. (WGS): Among the Best Multibagger Stocks to Buy According to Billionaires (Insider Monkey) +9.08%
Apr-21-25 09:57AM	Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results? (Zacks)
Apr-18-25 08:01AM	GeneDx Holdings Corp. (WGS) Rose on Robust Customer Demand (Insider Monkey)
Apr-16-25 04:02PM	IBD 50's GeneDx Inks $51 Million AI-Tied Takeover Deal (Investor's Business Daily)
06:00AM	GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale (Business Wire)
Apr-08-25 08:05AM	GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025 (Business Wire)
Apr-03-25 08:00AM	GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication (Business Wire) -5.61%
Apr-02-25 09:33AM	Buy 3 Momentum Anomaly Stocks as Markets Rise Despite Tariff Threats (Zacks)
Mar-22-25 05:48PM	Is GeneDx Holdings (WGS) The High Growth Low Debt Stock to Invest in Now? (InsiderMonkey)
Mar-20-25 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.94%
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:00AM	Zacks.com featured highlights DRDGOLD, GeneDx, EverQuote, HCI Group and Alibaba (Zacks) +7.32%
Mar-18-25 07:05AM	Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies (Business Wire)
Mar-13-25 08:30AM	GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting (Business Wire)
08:30AM	GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis (Business Wire)
Mar-07-25 07:00AM	How This Top Small-Cap Growth Fund Wins Big (Investor's Business Daily)
Mar-04-25 08:30AM	GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication (Business Wire)
Feb-24-25 11:00AM	Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols (Business Wire)
Feb-18-25 04:58PM	Top Biotech GeneDx Catapults 48% After Obliterating Earnings Forecasts (Investor's Business Daily) +47.69%
06:00AM	GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025 (Business Wire)
Feb-13-25 08:30AM	GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients (Business Wire) +9.91%
Feb-12-25 04:05PM	GeneDx to Participate in 45th Annual TD Cowen Health Care Conference (Business Wire)
Feb-10-25 08:30AM	GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment (Business Wire) +14.46%
Jan-28-25 04:30PM	GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025 (Business Wire) +5.85%
Jan-17-25 04:30PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.02%
Jan-14-25 09:25AM	GeneDx raises Q4 adjusted gross margin view to 68% from 64% (TipRanks) -15.30%
Jan-13-25 08:30AM	GeneDx Announces Preliminary 2024 Financial Results (Business Wire)
Jan-10-25 03:24PM	Outlook For These Biotechs Brightens As FDA Ushers In New Rules For Sector (Investor's Business Daily) -7.45%
Jan-09-25 08:30AM	GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers (Business Wire)
Jan-08-25 08:30AM	GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients (Business Wire)
Jan-06-25 04:04PM	IBD 50's GeneDx Adds To Nearly 2,700% Sprint With FDA Guide On AI (Investor's Business Daily) +13.23% +8.29%
01:39PM	IBD 50's GeneDx Surges On FDA Recommendations For AI Device Development (Investor's Business Daily)
Jan-04-25 08:00AM	Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly (Investor's Business Daily)
Jan-02-25 04:01PM	GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer (Business Wire)
Dec-30-24 01:00PM	How IBD Stock Of The Day GeneDx Landed On The IBD 50 And Notched A 2,500% Gain (Investor's Business Daily)
Dec-16-24 04:05PM	GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +6.72%
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Nov-25-24 01:26PM	This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win (Investor's Business Daily)
Nov-22-24 04:05PM	GeneDx to Participate in Upcoming Investor Conference (Business Wire) +9.21%
Nov-19-24 08:30AM	GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover (Business Wire)
Nov-18-24 08:30AM	GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary (Business Wire)
Nov-07-24 04:35PM	New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields (Business Wire)
Nov-04-24 04:35PM	GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting (Business Wire)
Oct-29-24 08:00AM	GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) +49.88%
Oct-24-24 11:10AM	Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening (Business Wire) +5.37%
Oct-08-24 08:30AM	GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns (Business Wire)
Oct-03-24 04:05PM	GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 (Business Wire) +5.73%
Sep-27-24 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.34%
Aug-12-24 04:05PM	GeneDx to Participate in Fall Investor Conferences (Business Wire)
Aug-09-24 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-30-24 08:57PM	WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) -10.57% +8.60%
04:05PM	GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
04:05PM	GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients (Business Wire)
Jul-12-24 12:00PM	All You Need to Know About GENEDX HOLDINGS (WGS) Rating Upgrade to Strong Buy (Zacks)
Jul-11-24 04:05PM	GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024 (GlobeNewswire) +9.36%
Jul-06-24 07:00AM	7 Small-Cap Stocks With Massive Potential Returns (InvestorPlace)
Jun-10-24 08:30AM	GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients (GlobeNewswire)
Jun-05-24 07:00AM	GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients (GlobeNewswire) +13.20%
May-22-24 04:05PM	GeneDx to Participate in Upcoming Investor Conferences (GlobeNewswire)

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stueland Katherine	Chief Executive Officer	Jun 16 '25	Option Exercise	0.00	18,750	0	25,098	Jun 18 04:14 PM
Stueland Katherine	Chief Executive Officer	Jun 16 '25	Sale	64.77	10,501	680,181	14,597	Jun 18 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 16 '25	Sale	64.77	3,729	241,539	8,769	Jun 18 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 09 '25	Option Exercise	0.00	2,462	0	6,567	Jun 11 04:05 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 09 '25	Sale	72.55	1,266	91,848	5,301	Jun 11 04:05 PM
Stueland Katherine	Chief Executive Officer	Jun 09 '25	Option Exercise	0.00	6,547	0	9,987	Jun 11 04:04 PM
Stueland Katherine	Chief Executive Officer	Jun 09 '25	Sale	72.55	3,639	264,009	6,348	Jun 11 04:04 PM
Kevin Feeley	Officer	Jun 09 '25	Proposed Sale	72.55	5,009	363,400		Jun 09 07:23 PM
Katherine Stueland	Officer	Jun 09 '25	Proposed Sale	72.55	14,139	1,025,800		Jun 09 07:22 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 01 '25	Option Exercise	0.00	718	0	4,475	Jun 03 05:30 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 02 '25	Sale	71.26	370	26,366	4,105	Jun 03 05:30 PM
Kevin Feeley	Officer	Jun 02 '25	Proposed Sale	71.35	370	26,400		Jun 02 08:55 PM
Meister Keith A.	Director	May 14 '25	Buy	60.16	50,000	3,007,997	3,058,629	May 16 04:00 PM
Meister Keith A.	Director	May 08 '25	Buy	56.01	100,000	5,600,994	3,008,629	May 12 07:46 PM
PFENNIGER RICHARD C JR	Director	May 02 '25	Option Exercise	0.00	918	0	28,582	May 05 04:48 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '25	Option Exercise	0.00	753	0	3,725	May 01 07:46 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '25	Sale	113.09	388	43,879	3,337	May 01 07:46 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '25	Option Exercise	0.00	3,874	0	5,594	May 01 07:44 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '25	Sale	113.09	2,154	243,596	3,440	May 01 07:44 PM
Kevin Feeley	Officer	Apr 29 '25	Proposed Sale	113.14	388	43,900		Apr 29 09:52 PM
Katherine Stueland	Director	Apr 29 '25	Proposed Sale	113.09	2,154	243,600		Apr 29 09:51 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Apr 14 '25	Proposed Sale	101.04	250,000	25,260,000		Apr 14 08:00 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 09 '25	Option Exercise	32.67	1,246	40,707	17,242	Apr 10 04:12 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 09 '25	Sale	92.18	15,516	1,430,334	1,726	Apr 10 04:12 PM
Stueland Katherine	Chief Executive Officer	Apr 09 '25	Sale	89.62	46,594	4,175,817	1,720	Apr 10 04:11 PM
Feeley Kevin	Officer	Apr 09 '25	Proposed Sale	91.80	14,270	1,310,000		Apr 09 05:36 PM
Stueland Katherine	Officer	Apr 09 '25	Proposed Sale	87.99	46,594	4,100,000		Apr 09 05:10 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 26 '25	Option Exercise	0.00	16,250	0	24,742	Mar 28 04:07 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 26 '25	Sale	95.61	8,746	836,211	15,996	Mar 28 04:07 PM
Stueland Katherine	Chief Executive Officer	Mar 26 '25	Option Exercise	0.00	80,000	0	94,865	Mar 28 04:07 PM
Stueland Katherine	Chief Executive Officer	Mar 26 '25	Sale	95.62	46,551	4,451,084	48,314	Mar 28 04:07 PM
Kevin Feeley	Officer	Mar 26 '25	Proposed Sale	95.61	8,746	836,200		Mar 26 06:36 PM
Katherine Stueland	Director	Mar 26 '25	Proposed Sale	95.62	46,551	4,451,200		Mar 26 06:34 PM
Stueland Katherine	Chief Executive Officer	Mar 16 '25	Option Exercise	0.00	18,750	0	25,424	Mar 17 09:51 PM
Stueland Katherine	Chief Executive Officer	Mar 17 '25	Sale	96.71	10,559	1,021,146	14,865	Mar 17 09:51 PM
Stueland Katherine	Chief Executive Officer	Mar 13 '25	Sale	89.44	1,078	96,420	6,674	Mar 17 09:51 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 17 '25	Sale	96.71	3,749	362,565	8,492	Mar 17 09:50 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 13 '25	Sale	90.05	402	36,202	5,044	Mar 17 09:50 PM
Kevin Feeley	Officer	Mar 17 '25	Proposed Sale	96.72	3,749	362,600		Mar 17 06:46 PM
Katherine Stueland	Director	Mar 17 '25	Proposed Sale	96.70	10,559	1,021,100		Mar 17 06:44 PM
Kevin Feeley	Officer	Mar 13 '25	Proposed Sale	90.05	402	36,200		Mar 13 07:04 PM
Katherine Stueland	Officer	Mar 13 '25	Proposed Sale	89.42	1,078	96,400		Mar 13 07:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 09 '25	Option Exercise	0.00	2,462	0	6,368	Mar 11 05:42 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 10 '25	Sale	94.72	922	87,334	5,446	Mar 11 05:42 PM
Stueland Katherine	Chief Executive Officer	Mar 09 '25	Option Exercise	0.00	6,546	0	10,483	Mar 11 05:40 PM
Stueland Katherine	Chief Executive Officer	Mar 10 '25	Sale	94.73	2,731	258,695	7,752	Mar 11 05:40 PM
Kevin Feeley	Officer	Mar 10 '25	Proposed Sale	94.69	922	87,300		Mar 10 07:44 PM
Katherine Stueland	Officer	Mar 10 '25	Proposed Sale	94.73	2,731	258,700		Mar 10 07:43 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 01 '25	Option Exercise	0.00	717	0	4,167	Mar 04 04:36 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 03 '25	Sale	103.94	261	27,128	3,906	Mar 04 04:36 PM
Kevin Feeley	Officer	Mar 03 '25	Proposed Sale	103.83	261	27,100		Mar 03 06:59 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Feb 24 '25	Proposed Sale	95.83	373,569	35,799,117		Feb 24 08:00 PM
RUCH JOSHUA	Director	Feb 05 '25	Option Exercise	7.89	5,816	45,888	16,799	Feb 07 04:01 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 29 '25	Option Exercise	0.00	753	0	3,225	Jan 31 05:47 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 29 '25	Sale	78.48	275	21,582	2,950	Jan 31 05:47 PM
Stueland Katherine	Chief Executive Officer	Jan 29 '25	Option Exercise	0.00	3,874	0	5,594	Jan 31 05:46 PM
Stueland Katherine	Chief Executive Officer	Jan 29 '25	Sale	78.48	1,657	130,046	3,937	Jan 31 05:46 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Jan 30 '25	Proposed Sale	77.86	1,346,123	104,809,137		Jan 30 08:02 PM
Kevin Feeley	Officer	Jan 29 '25	Proposed Sale	78.55	275	21,600		Jan 29 09:06 PM
Katherine Stueland	Director	Jan 29 '25	Proposed Sale	78.46	1,657	130,000		Jan 29 09:04 PM
RUCH JOSHUA	Director	Jan 17 '25	Option Exercise	7.89	3,000	23,670	10,983	Jan 22 05:08 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 07 '25	Option Exercise	32.67	11,208	366,165	37,978	Jan 10 05:54 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 07 '25	Sale	93.82	35,506	3,331,024	2,472	Jan 10 05:54 PM
Stueland Katherine	Chief Executive Officer	Jan 07 '25	Sale	94.48	51,420	4,858,119	1,720	Jan 10 05:53 PM
Feeley Kevin	Officer	Jan 07 '25	Proposed Sale	94.07	35,506	3,340,000		Jan 07 05:02 PM
Stueland Katherine	Officer	Jan 07 '25	Proposed Sale	93.93	51,420	4,830,000		Jan 07 04:44 PM
Stueland Katherine	Chief Executive Officer	Jan 02 '25	Sale	78.18	18,006	1,407,686	53,140	Jan 06 06:05 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 02 '25	Sale	76.04	1,430	108,737	26,770	Jan 06 06:04 PM
Feeley Kevin	Officer	Jan 02 '25	Proposed Sale	75.52	1,430	108,000		Jan 02 05:03 PM
Stueland Katherine	Officer	Jan 02 '25	Proposed Sale	77.75	18,006	1,400,000		Jan 02 04:31 PM
Stueland Katherine	Chief Executive Officer	Dec 16 '24	Option Exercise	0.00	18,750	0	81,647	Dec 18 06:22 PM
Stueland Katherine	Chief Executive Officer	Dec 16 '24	Sale	76.75	10,501	805,995	71,146	Dec 18 06:22 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 16 '24	Option Exercise	0.00	7,197	0	31,928	Dec 18 06:21 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 16 '24	Sale	76.75	3,728	286,139	28,200	Dec 18 06:21 PM
Kevin Feeley	Officer	Dec 16 '24	Proposed Sale	76.75	3,728	286,139		Dec 16 08:41 PM
Katherine Stueland	Officer	Dec 16 '24	Proposed Sale	76.75	10,501	805,995		Dec 16 08:40 PM
Stueland Katherine	Chief Executive Officer	Dec 09 '24	Option Exercise	0.00	6,547	0	66,558	Dec 11 07:19 PM
Stueland Katherine	Chief Executive Officer	Dec 09 '24	Sale	76.37	3,661	279,598	62,897	Dec 11 07:19 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 09 '24	Option Exercise	0.00	2,462	0	25,868	Dec 11 07:18 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 09 '24	Sale	76.37	1,137	86,836	24,731	Dec 11 07:18 PM
Kevin Feeley	Officer	Dec 09 '24	Proposed Sale	76.37	1,137	86,836		Dec 09 08:06 PM
Katherine Stueland	Director	Dec 09 '24	Proposed Sale	76.37	3,661	279,598		Dec 09 08:05 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 01 '24	Option Exercise	0.00	718	0	23,669	Dec 03 07:21 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 02 '24	Sale	78.39	263	20,617	23,406	Dec 03 07:21 PM
Kevin Feeley	Officer	Dec 02 '24	Proposed Sale	78.39	263	20,617		Dec 02 08:01 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Nov 21 '24	Sale	73.76	12,019	886,568	32,932	Nov 25 06:21 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Nov 22 '24	Sale	76.07	9,981	759,242	22,951	Nov 25 06:21 PM
Ryan Jason	Director	Nov 19 '24	Sale	71.28	31,510	2,246,130	15,490	Nov 21 08:21 PM
Ryan Jason	Director	Nov 20 '24	Sale	69.13	15,490	1,070,749	0	Nov 21 08:21 PM
Feeley Kevin	Officer	Nov 21 '24	Proposed Sale	72.73	22,000	1,600,000		Nov 21 06:14 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Nov 18 '24	Sale	70.78	126,782	8,973,059	2,719,692	Nov 19 08:00 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Nov 15 '24	Sale	69.78	20,359	1,420,663	2,846,474	Nov 19 08:00 PM
Stueland Katherine	Chief Executive Officer	Nov 15 '24	Sale	70.48	23,108	1,628,593	82,318	Nov 19 07:05 PM
Stueland Katherine	Chief Executive Officer	Nov 18 '24	Sale	70.34	22,307	1,569,091	60,011	Nov 19 07:05 PM
Ryan Jason	Officer	Nov 19 '24	Proposed Sale	70.00	47,000	3,290,000		Nov 19 05:10 PM
Stueland Katherine	Officer	Nov 15 '24	Proposed Sale	70.02	45,415	3,180,000		Nov 15 04:58 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Oct 31 '24	Sale	75.00	865,800	64,935,000	2,866,833	Nov 04 05:01 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Oct 31 '24	Proposed Sale	81.69	1,012,941	82,747,150		Oct 31 08:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Oct 29 '24	Option Exercise	0.00	753	0	45,225	Oct 31 05:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Oct 29 '24	Sale	66.60	274	18,248	44,951	Oct 31 05:14 PM

OPK

Opko Health Inc

WGS

GeneDx Holdings Corp

Upgrade your FINVIZ experience